{"DataElement":{"publicId":"6029702","version":"1","preferredName":"Stage Prognostic Factor National Program of Cancer Registries Derived Neoplasm Clinical Stage Group Code","preferredDefinition":"This item is needed to store the results of NPCRÂ’s derived algorithmic calculation of clinical stage group based on AJCC T, N, and M and relevant biomarkers and prognostic factors.","longName":"6029563v1.0:6028002v1.0","context":"PS-CC","contextVersion":"1","DataElementConcept":{"publicId":"6029563","version":"1","preferredName":"Stage Prognostic Factor National Program of Cancer Registries Derivation Neoplasm Clinical Stage Group","preferredDefinition":"The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body._The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome._Established by Congress through the Cancer Registries Amendment Act in 1992, and administered by CDC, the National Program of Cancer Registries (NPCR) collects data on cancer occurrence (including the type, extent, and location of the cancer), the type of initial treatment, and outcomes. It supports central cancer registries in 46 states, the District of Columbia, Puerto Rico, the U.S. Pacific Island Jurisdictions, and the U.S. Virgin Islands._The source from which something comes or issues; to take, obtain, or receive from a source._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body._Any number of entities (members) considered as a unit.","longName":"2688190v1.0:6029561v1.0","context":"PS-CC","contextVersion":"1","ObjectClass":{"publicId":"2688190","version":"1","preferredName":"Stage Prognostic Factor","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.:The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome.","longName":"C16899:C18959","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prognostic Factor","conceptCode":"C18959","definition":"The general personal and health characteristics that have a bearing on the course of a disease and its eventual outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C0FC8A1-D62E-5124-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2007-10-09","modifiedBy":"ONEDATA","dateModified":"2007-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6029561","version":"1","preferredName":"National Program of Cancer Registries Derivation Neoplasm Clinical Stage Group","preferredDefinition":"Established by Congress through the Cancer Registries Amendment Act in 1992, and administered by CDC, the National Program of Cancer Registries (NPCR) collects data on cancer occurrence (including the type, extent, and location of the cancer), the type of initial treatment, and outcomes. It supports central cancer registries in 46 states, the District of Columbia, Puerto Rico, the U.S. Pacific Island Jurisdictions, and the U.S. Virgin Islands.:The source from which something comes or issues; to take, obtain, or receive from a source.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.:Any number of entities (members) considered as a unit.","longName":"6029561v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Program of Cancer Registries","conceptCode":"C141462","definition":"Established by Congress through the Cancer Registries Amendment Act in 1992, and administered by CDC, the National Program of Cancer Registries (NPCR) collects data on cancer occurrence (including the type, extent, and location of the cancer), the type of initial treatment, and outcomes. It supports central cancer registries in 46 states, the District of Columbia, Puerto Rico, the U.S. Pacific Island Jurisdictions, and the U.S. Virgin Islands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Derivation","conceptCode":"C42885","definition":"The source from which something comes or issues; to take, obtain, or receive from a source.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical","conceptCode":"C25398","definition":"Relating to the examination and treatment of patients dependent on direct observation.  The term may also refer to the institution (clinic) providing this activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Group","conceptCode":"C43359","definition":"Any number of entities (members) considered as a unit.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E332DEF-0B9E-70C3-E053-F662850AC4E8","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-17","modifiedBy":"ONEDATA","dateModified":"2017-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E332DEF-0BAF-70C3-E053-F662850AC4E8","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-17","modifiedBy":"HARTLEYG","dateModified":"2018-11-06","changeDescription":"Curated to support NAACCR v16_11.16.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6028002","version":"1","preferredName":"National Program of Cancer Registries Clinical Stage Group Code","preferredDefinition":"A symbol or combination of symbols which is assigned to the members of a collection.","longName":"6028002v1.0","context":"PS-CC","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261841","version":"1","preferredName":"Code","preferredDefinition":"A system of numbered categories for representation of data.","longName":"C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-6427-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-07-13","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D967ECB-A804-2959-E053-F662850ADA83","latestVersionIndicator":"Yes","beginDate":"2017-11-09","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-09","modifiedBy":"HARTLEYG","dateModified":"2018-11-06","changeDescription":"Curated to support NAACCR v16_11.09.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2193114","version":"1","longName":"Division of Cancer Control and Population Sciences","context":"PS-CC","ClassificationSchemeItems":[{"publicId":"5899845","version":"1","longName":"StageProgFactors16","context":"PS-CC"},{"publicId":"5899833","version":"1","longName":"NAACCR 16","context":"PS-CC"},{"publicId":"7464305","version":"1","longName":"NAACCR 18","context":"PS-CC"},{"publicId":"7464319","version":"1","longName":"StageProgFactors18","context":"PS-CC"}]}],"AlternateNames":[{"name":"NPCR Derived Clin Stg Grp","type":"NAACCR Item Name","context":"PS-CC"},{"name":"3650","type":"NAACCR Item #","context":"PS-CC"}],"ReferenceDocuments":[{"name":"NAACCR 16, Data Stds/Dict.","type":"REFERENCE","description":"For additional details see NAACCR, Standards for Cancer Registries Volume II, Version 16 Data Standards and Data Dictionary (01/2016)","url":"https://www.naaccr.org/data-standards-data-dictionary/","context":"PS-CC"},{"name":"NPCR Derived Clinical Stage G","type":"Preferred Question Text","description":"NPCR Derived Clinical Stage Group","url":null,"context":"PS-CC"},{"name":"Valid Values","type":"VALID_VALUE_SOURCE","description":"See NAACCR 16, Data Stds/Dictionary, Data Dictionary section for a list of code sources and coding instructions.","url":"https://www.naaccr.org/data-standards-data-dictionary/","context":"PS-CC"}],"origin":"NAACCR:North American Association of Central Cancer Registries","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E3320CB-AA70-5C4C-E053-F662850A65F9","latestVersionIndicator":"Yes","beginDate":"2017-11-17","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-11-17","modifiedBy":"HARTLEYG","dateModified":"2018-11-06","changeDescription":"Curated to support NAACCR v16_11.16.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}